These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1678925)

  • 41. Adjunctive sympathoplegic therapy to ACE inhibition in Blacks with congestive heart failure: a comparison of alpha-1 with beta-1 blockade on exercise tolerance and cardiac sympathovagal reflex activity.
    Ajayi AA; Sofowora GG; Adigun AQ; Asiyanbola B
    Ethn Dis; 2003; 13(1):71-9. PubMed ID: 12723015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term efficacy and safety of terazosin.
    Cohen J
    J Clin Pharmacol; 1993 Mar; 33(3):272-8. PubMed ID: 8096524
    [No Abstract]   [Full Text] [Related]  

  • 43. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis.
    Lowe FC
    Urology; 1994 Jul; 44(1):46-51. PubMed ID: 7518981
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
    Torvik D; Madsbu HP
    Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Terazosin: an effective once-daily monotherapy for the treatment of hypertension.
    Dauer AD
    Am J Med; 1986 May; 80(5B):29-34. PubMed ID: 2872804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy.
    Englert RG; Mauersberger H
    Am Heart J; 1988 Dec; 116(6 Pt 2):1826-32. PubMed ID: 2904758
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical trials with terazosin. General methods.
    Sperzel WD; Luther RR; Glassman HN
    Am J Med; 1986 May; 80(5B):25-8. PubMed ID: 2872803
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of alpha 1-blockers in combination therapy for hypertension.
    Zusman RM
    Int J Clin Pract; 2000; 54(1):36-40. PubMed ID: 10750258
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy.
    Rosenthal J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1763-6. PubMed ID: 2904747
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the effects of terazosin and enalapril on laboratory stress testing blood pressure in patients with essential hypertension.
    Cardillo C; Degen C; Campia U; De Felice F; Folli G
    J Clin Pharmacol; 1993 May; 33(5):433-8. PubMed ID: 8101194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine.
    Lindner UK; von Manteuffel GE; Stafunsky M
    Am Heart J; 1988 Dec; 116(6 Pt 2):1814-20. PubMed ID: 2904756
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension.
    Ott P; Storm TL; Krusell LR; Jensen H; Badskjaer J; Faergeman O
    Am J Cardiol; 1987 May; 59(14):73G-77G. PubMed ID: 2884856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antihypertensive therapy with once-daily administration of terazosin, a new alpha 1-adrenergic-receptor blocker.
    Abraham PA; Halstenson CE; Matzke GR; Napier JL; Keane WF
    Pharmacotherapy; 1985; 5(5):285-9. PubMed ID: 2866492
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antihypertensive therapy: taking lipids into consideration.
    Grimm RH
    Am Heart J; 1991 Sep; 122(3 Pt 2):910-8. PubMed ID: 1678922
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment.
    Tomoda F; Takata M; Yoshida K; Yasumoto K; Mikawa M; Sasayama S
    Am J Hypertens; 1989 Nov; 2(11 Pt 1):834-9. PubMed ID: 2574044
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A multicenter study of doxazosin in the treatment of severe essential hypertension.
    Soltero I; Guevara J; Silva H; Velasco M
    Am Heart J; 1988 Dec; 116(6 Pt 2):1767-71. PubMed ID: 2904748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of doxazosin in hypertension therapy.
    Hayduk K
    Am J Cardiol; 1987 May; 59(14):35G-39G. PubMed ID: 2884851
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A double-blind comparative study of doxazosin and nitrendipine in patients with mild-to-moderate essential hypertension.
    Nechwatal W; Berger J; Blumrich W; Bouzo H; Brandl K; Braun S; Laukaitis A; Müller G; Ryba W; Schreiegg J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1806-14. PubMed ID: 2904755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. alpha 1-antagonists in the treatment of hypertension.
    Grimm RH
    Hypertension; 1989 May; 13(5 Suppl):I131-6. PubMed ID: 2577457
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Pressure and metabolic effects of terazosin in essential hypertension].
    Valle R; Semplicini A; Serena L; Gebbin A; Fontebasso A; Gerardi G; De Toni R; Pessina AC
    Cardiologia; 1994 Jun; 39(6):421-4. PubMed ID: 7923256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.